Buy TCB-2

Description

4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide (TCB-2) is a synthetic chemical compound used in scientific research as a selective agonist for the serotonin 5-HT2A receptor. [, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ] This receptor, a type of G protein-coupled receptor, is found throughout the central nervous system and plays a critical role in various physiological processes, including cognition, perception, and mood. [, , , , ,

] TCB-2’s selectivity for the 5-HT2A receptor makes it a valuable tool for researchers investigating the role of this receptor in both normal and pathological conditions.
Related Compounds
Psilocin

Compound Description: Psilocin is a naturally occurring psychedelic compound and a potent agonist of the serotonin 5-HT2A receptor. It is the pharmacologically active metabolite of psilocybin, found in certain species of mushrooms. Psilocin has been shown to have antidepressant-like effects in animal models of depression, possibly mediated through 5-HT2A receptor activation [

].

Relevance: Like TCB-2, psilocin acts as an agonist at the 5-HT2A receptor, suggesting a shared mechanism of action for their observed pharmacological effects. Notably, psilocin demonstrates sustained antidepressant effects in the forced swim test (FST) in mice, lasting up to three weeks after a single administration [
]. This prolonged duration of action differentiates psilocin from TCB-2, which did not exhibit such long-lasting effects [

].
DOI ((±)-2,5-Dimethoxy-4-iodoamphetamine)

Compound Description: DOI is a synthetic psychedelic drug and a potent agonist of the 5-HT2A receptor. It is often used as a pharmacological tool to investigate the role of 5-HT2A receptors in various physiological and behavioral processes [

].
MDL 100907 [(R)-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol]

Compound Description: MDL 100907 is a highly selective antagonist of the serotonin 5-HT2A receptor. It is commonly used in research to block the effects of 5-HT2A receptor agonists, such as TCB-2 [

].

Relevance: MDL 100907 serves as a valuable tool to confirm the involvement of the 5-HT2A receptor in the pharmacological effects observed with TCB-2 [
]. By blocking the receptor, MDL 100907 can prevent or reverse the effects of TCB-2, demonstrating that those effects are indeed mediated by the 5-HT2A receptor [,

].
Ketanserin

Compound Description: Ketanserin is a serotonin receptor antagonist with high affinity for both 5-HT2A and 5-HT2C receptors. It is clinically used for the treatment of hypertension [
,

].

Relevance: Ketanserin’s ability to block both 5-HT2A and 5-HT2C receptors distinguishes it from TCB-2, which selectively targets the 5-HT2A receptor [
, ]. Ketanserin is often used to assess the contribution of both receptor subtypes to specific physiological or behavioral effects [, ]. In the context of the provided research, Ketanserin was used as a negative control in the [35S]GTPγS binding assays, demonstrating its binding affinity for 5-HT2A receptors without inducing G protein activation [

].
8-OH-DPAT (8-Hydroxy-2-(di-n-propylamino)tetralin)

Compound Description: 8-OH-DPAT is a research compound with high affinity for the serotonin 5-HT1A receptor, acting as an agonist. This receptor is involved in various physiological processes, including mood, anxiety, and sleep [
,

].

Relevance: 8-OH-DPAT’s action on the 5-HT1A receptor differentiates it from TCB-2, which specifically targets the 5-HT2A receptor [
, ]. Studies using 8-OH-DPAT alongside TCB-2 help dissect the distinct roles of 5-HT1A and 5-HT2A receptors in modulating neuronal activity and physiological responses [,

].
BW723C86

Compound Description: BW723C86 is a selective agonist of the serotonin 5-HT2B receptor. It is primarily used as a research tool to study the role of this receptor subtype in various physiological processes, particularly in the cardiovascular system [
,

].

Relevance: BW723C86 is structurally similar to TCB-2, but its selectivity for the 5-HT2B receptor distinguishes it from TCB-2’s selective action on the 5-HT2A receptor [
, ]. Investigating the effects of both compounds allows researchers to understand the specific contributions of these closely related serotonin receptor subtypes [,

].
NBOH-2C-CN

Compound Description: NBOH-2C-CN is a potent and selective agonist of the serotonin 5-HT2A receptor, often used in research to study the effects of activating this receptor subtype [

].

Relevance: NBOH-2C-CN shares a similar pharmacological profile with TCB-2, both acting as potent agonists of the 5-HT2A receptor [
]. Comparing their effects in different experimental models can provide valuable insights into the specific roles of 5-HT2A receptors in various physiological and behavioral processes [

].
Rizatriptan benzoate

Compound Description: Rizatriptan benzoate is a medication primarily used to treat migraine headaches. It acts as an agonist at serotonin 5-HT1B and 5-HT1D receptors, which are involved in constricting blood vessels in the brain [

].

Relevance: While Rizatriptan benzoate targets the 5-HT1B/1D receptors for vasoconstriction, TCB-2 exerts its effects through the 5-HT2A receptor [
]. This difference highlights the diverse roles of various serotonin receptor subtypes in vascular regulation, with TCB-2 influencing 5-HT2A receptors in the context of ergot alkaloid-induced vasoconstriction [, ].